← Oncology Approval Tracker

FDA DECISION ·

Rybrevant Faspro

amivantamab + hyaluronidase-lpuj · Janssen Biotech

FDA approvalNew formulationNon-small cell lung cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous treatment for adults across the NSCLC indications approved for intravenous amivantamab, with the regimen determined by EGFR alteration, prior therapy, and treatment setting.

LAMPGEN ANALYSIS

Why it matters

The alternate route showed comparable drug exposure with fewer systemic administration reactions than IV amivantamab in the studied combination.

What research teams should watch

Use the route-specific schedule, review indication-specific companion therapy, and preserve reaction monitoring when changing administration.

PRIMARY RECORDS

Sources